|
Variable
|
PFS
|
OS
|
DMFS
|
LRRFS
|
LRFS
|
RRFS
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Age
|
0.827 (0.408–1.675)
|
0.598
|
1.604 (0.625–4.113)
|
0.326
|
0.440 (0.148–1.308)
|
0.140
|
0.728 (0.331–1.600)
|
0.429
|
0.619 (0.224–1.715)
|
0.357
|
1.328 (0.507–3.479)
|
0.564
|
|
Sex
|
0.699 (0.336–1.454)
|
0.338
|
0.503 (0.164–1.542)
|
0.230
|
0.467 (0.148–1.472)
|
0.194
|
0.533 (0.237–1.197)
|
0.127
|
0.531 (0.189–1.492)
|
0.230
|
0.585 (0.211–1.619)
|
0.302
|
|
T stage
|
2.739 (1.173–6.397)
|
0.020
|
4.114 (1.140–14.847)
|
0.031
|
10.722 (2.408–47.740)
|
0.002
|
1.536 (0.611–3.861)
|
0.361
|
1.433 (0.437–4.702)
|
0.553
|
2.606 (0.803–8.465)
|
0.111
|
|
N stage
|
2.735 (0.761–9.837)
|
0.123
|
2.530 (0.577–11.090)
|
0.218
|
9.408 (1.465–60.435)
|
0.018
|
1.475 (0.367–5.927)
|
0.583
|
2.379 (0.359–15.749)
|
0.369
|
2.085 (0.416–10.446)
|
0.372
|
|
Clinical stage
|
0.516 (0.214–1.246)
|
0.142
|
1.309 (0.421–4.071)
|
0.642
|
0.384 (0.095–1.549)
|
0.179
|
0.637 (0.266–1.530)
|
0.313
|
0.408 (0.120–1.392)
|
0.152
|
0.740 (0.244–2.242)
|
0.594
|
|
EBV DNA before first treatment
|
1.360 (0.658–2.811)
|
0.407
|
0.777 (0.276–2.184)
|
0.632
|
1.639 (0.548–4.901)
|
0.377
|
1.912 (0.843–4..338)
|
0.121
|
1.000 (0.357–2.798)
|
0.999
|
3.576 (1.010–12.658)
|
0.048
|
|
Preoperative EBV DNA
|
1.546 (0.758–3.151)
|
0.231
|
5.535 (1.677–18.268)
|
0.005
|
1.898 (0.655–5.499)
|
0.238
|
1.571 (0.733–3.365)
|
0.245
|
2.622 (0.944–7.286)
|
0.064
|
2.804 (1.018–7.727)
|
0.046
|
|
Postoperative pathological result
|
5.209 (1.185–22.900)
|
0.029
|
–
|
–
|
9.265 (1.035–82.935)
|
0.047
|
10.175 (1.273–81.320)
|
0.029
|
4.158 (0.457–37.820)
|
0.206
|
–
|
–
|
|
Treatment for NPC
|
1.282 (0.780–2.108)
|
0.327
|
1.702 (0.711–4.070)
|
0.232
|
2.619 (0.929–7.383)
|
0.069
|
1.141 (0.672–1.938)
|
0.626
|
0.865 (0.476–1.573)
|
0.635
|
2.398 (0.971–5.922)
|
0.058
|
- NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
- All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), postoperative pathology (positive vs. negative), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)
